SCHEMBL5871435

SCHEMBL5871435

COC(=O)C(Cc1[c]ccc(C(F)(F)F)c1)C(=O)OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRB P23467 1/20 0.38
CFTR P13569 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
NOS3 P29474 4/20 0.37
NOS1 P29475 4/20 0.37
NOS2 P35228 4/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAPK1 P28482 1/20 0.36
KDM4E B2RXH2 2/20 0.35
MAPT P10636 1/20 0.35
USP2 O75604 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C9 P11712 2/20 0.35
NR1I2 O75469 1/20 0.35
ADRB1 P08588 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADRA2B P18089 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871875 0.80 ESR1 (0.39) PTPRBPPARGPPARDPPARA
SCHEMBL5872106 0.80 PPARG (0.40) PTPRBSMN1; SMN2USP2CYP1A2CYP2C9
SCHEMBL5872194 0.78 ACHE (0.39) PTPRBSMN1; SMN2NOS3NOS1NOS2
SCHEMBL5871796 0.78 PPARG (0.39) PTPRBMAPK1KDM4ECYP1A2CYP2C9
SCHEMBL3104276 0.76 HTR2A (0.41) MAPTCYP3A4CYP1A2ADRA2CHTR2A
SCHEMBL5872122 0.75 PTPRB (0.41) PTPRBNOS3NOS1NOS2USP2
SCHEMBL28017508 0.74 HTR2A (0.56) SMN1; SMN2NPSR1KDM4EMAPTUSP2
SCHEMBL5872069 0.73 PTPRB (0.43) PTPRBMAPTCYP2C9PPARGPPARD
SCHEMBL5872007 0.73 MAPT (0.40) SMN1; SMN2NPSR1MAPTCYP1A2CYP2C9
SCHEMBL7523504 0.72 IDO1 (0.35) CFTRSMN1; SMN2KDM4ECYP1A2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071187-B2 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2006-07-04 US disclosed
US-20040214853-A1 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-10-28 US disclosed
EP-1426374-A1 NAPHTHYRIDINE DERIVATIVE OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214853-A1 Naphthyridine derivatives MT-ND1, OPRD1, NR0B1 PTPRB 3070/4885CFTR 3918/4885SMN1; SMN2 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.